Abiopharma

🔍 Dang Kimberly A (Director)

Company: KINDER MORGAN, INC. (KMI)

Report Date: 2026-07-31

Detailed Transactions and Holdings:

• Acquired 636,575 shares of Class P Common Stock (Direct)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,467,176.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 250,233 shares of Class P Common Stock at $32.18 per share (Direct)
  Date: 2026-07-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,216,943.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Holds 0 shares of Class P Common Stock (Direct)
  Date: 2026-07-31 | Code: H | nature_of_ownership: By Limited Partnership | shares_owned_after: 2,026,048.00 | Footnotes: F4
• Sold 636,575 shares of Restricted Stock Unit (Derivative)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: This transaction represents the settlement of restricted stock units in shares of Class P Common Stock on their scheduled vesting date.
• F2: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the reported vesting of restricted stock units.
• F3: Closing price of Class P Common Stock on the date of vesting.
• F4: The reporting person disclaims 10% of any beneficial ownership of the shares owned by such limited partnership.
• F5: Each restricted stock unit represents the right to receive, at settlement, one share of Class P Common Stock.
• F6: These restricted stock units vested on July 31, 2026.